ROME Therapeutics: ROME Therapeutics to Present Data Supporting LINE-1 Reverse Transcriptase Inhibitors as a Novel Treatment for Autoimmune Diseases at ACR Convergence 2024

BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ROME Therapeutics, a biotechnology company illuminating the intersection of the dark genome and innate immunity to develop breakthrough medicines for autoimmune and neurodegenerative diseases, today announced that it will present preclinical and non-interventional clinical data on its novel LINE-1 RT inhibitors at the American College of Rheumatology (ACR) annual meeting, ACR Convergence 2024, which will be held November 14-19 in Washington, D.C. Building on previous findings shared by ROME, the new data further demonstrate the ability of the company's LINE-1 RT inhibitors to suppress aberrant activation of Type 1 interferon signaling and their potential as a new class of therapeutics to address diseases known as Type 1 interferonopathies, such as Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE) and other autoimmune diseases.ROME is the pioneer and leader in understanding and drugging LINE-1 RT, a ...Full story available on Benzinga.com